Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Ultragenyx Pharmaceutical (RARE) Shares Issued (2016 - 2024)

Ultragenyx Pharmaceutical has reported Shares Issued over the past 8 years, most recently at $381.0 million for Q2 2024.

  • Quarterly Shares Issued changed N/A to $381.0 million in Q2 2024 from the year-ago period, while the trailing twelve-month figure was $390.1 million through Jun 2024, changed N/A year-over-year, with the annual reading at $6.0 million for FY2025, 45.45% down from the prior year.
  • Shares Issued was $381.0 million for Q2 2024 at Ultragenyx Pharmaceutical, up from $2.0 million in the prior quarter.
  • Over five years, Shares Issued peaked at $381.0 million in Q2 2024 and troughed at $380000.0 in Q1 2020.
  • The 4-year median for Shares Issued is $9.8 million (2021), against an average of $45.3 million.
  • The largest YoY upside for Shares Issued was 3258.16% in 2021 against a maximum downside of 91.32% in 2021.
  • A 4-year view of Shares Issued shows it stood at $79.8 million in 2020, then tumbled by 91.32% to $6.9 million in 2021, then crashed by 71.1% to $2.0 million in 2022, then skyrocketed by 18940.48% to $381.0 million in 2024.
  • Per Business Quant, the three most recent readings for RARE's Shares Issued are $381.0 million (Q2 2024), $2.0 million (Q4 2022), and $1.1 million (Q3 2022).